Intragastric Balloon Versus Endoscopic Sleeve Gastroplasty for the Treatment of Obesity: a Systematic Review and Meta-analysis

Singh, Shailendra; Khan, Ahmad; Bilal, Mohammad; Chowdhry, Monica; Ryan, Michele B.; Bazarbashi, Ahmad Najdat; Thompson, Christopher C.

doi:10.1007/s11695-020-04644-8

Cited by 35 publications

(26 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Singh et al also conducted a systematic review and meta-analysis comparing the efficacy, safety, and durability of IGB versus endoscopic sleeve gastroplasty (ESG). 50 They found that the mean %TWL at 12-month follow-up with ESG was 17.5% as compared to 10.3% with IGB placement. 50 While weight reduction can be achieved significantly by IGB placement, it should be noted that the effect may only be short-term due to regain of weight within one year after removal, as reported in some studies.…”

Section: Weight Loss and Metabolic Effects Of Intra-gastric Balloonsmentioning

confidence: 96%

“…In another meta-analysis, Kotinda et al [ 49 ] reviewed 13 RCTs involving 1,523 patients using either the Orbera, Reshape Duo, Obalon, Spatz, or Heliosphere, which compared IGB with sham or lifestyle intervention, and showed that the difference in mean %EWL and % total weight loss (%TWL) at follow-up was 17.9%, and 4.4%, respectively, and was significantly higher in the IGB group. Singh et al also conducted a systematic review and meta-analysis comparing the efficacy, safety, and durability of IGB versus endoscopic sleeve gastroplasty (ESG) [ 50 ]. They found that the mean %TWL at 12-month follow-up with ESG was 17.5% as compared to 10.3% with IGB placement [ 50 ].…”

Section: Weight Loss and Metabolic Effects Of Intra-gastric Balloonsmentioning

confidence: 99%

“…Singh et al also conducted a systematic review and meta-analysis comparing the efficacy, safety, and durability of IGB versus endoscopic sleeve gastroplasty (ESG) [ 50 ]. They found that the mean %TWL at 12-month follow-up with ESG was 17.5% as compared to 10.3% with IGB placement [ 50 ].…”

Section: Weight Loss and Metabolic Effects Of Intra-gastric Balloonsmentioning

confidence: 99%

See 2 more Smart Citations

The Clinical and Metabolic Effects of Intragastric Balloon on Morbid Obesity and Its Related Comorbidities

et al. 2021

Self Cite

View full text Add to dashboard Cite

Obesity is becoming increasingly prevalent worldwide, and its metabolic sequelae lead to a significant burden on healthcare resources. Options for the management of obesity include lifestyle modification, pharmacological treatment, surgery, and endoscopic bariatric therapies (EBTs). Among these, EBTs are more effective than diet and lifestyle modification and are less invasive than bariatric surgery. In recent years, there have been significant advances in technologies pertaining to EBTs. Of all the available EBTs, there is a significant amount of clinical experience and published data regarding intragastric balloons (IGBs) because of their comparatively long development period. Currently, the United States Food and Drug Administration (FDA) has approved three IGBs, including Orbera (Apollo Endosurgery, Austin, TX, USA), ReShape Duo (ReShape Medical, San Clemente, CA, USA), and Obalon (Obalon Therapeutics, Carlsbad, CA, USA). The aim of this review is to summarize the available literature on the efficacy of IGBs in weight loss and their impact on obesity-related metabolic diseases.

show abstract

Section: Weight Loss and Metabolic Effects Of Intra-gastric Balloonsmentioning

confidence: 96%

Section: Weight Loss and Metabolic Effects Of Intra-gastric Balloonsmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical and Metabolic Effects of Intragastric Balloon on Morbid Obesity and Its Related Comorbidities

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In another meta-analysis of eight studies with 1,815 ESG patients and seven studies with 2,179 LSG patients, the pooled rates of %TBWL with LSG were statistically superior at 12 months to the rates with ESG (30.5% vs. 17.1%, p =0.001) [ 21 ]. Current evidence indicates that ESG offers satisfactory efficacy in patients with mild-to moderate and inferior efficacy to LSG in those with severe obesity; it is better than other endoscopic procedures like intra-gastric balloon [ 22 ].…”

Section: Comparison Of Endoscopic Sleeve Gastroplasty and Laparoscopimentioning

confidence: 99%

The Efficacy and Safety of Endoscopic Sleeve Gastroplasty as an Alternative to Laparoscopic Sleeve Gastrectomy

Yoon

Arau

2021

Clin Endosc

View full text Add to dashboard Cite

Endoscopic sleeve gastroplasty (ESG) is a therapeutic endoscopic technique for reducing the size of the gastric reservoir in obese patients, using a full-thickness endoscopic suturing device. The effectiveness of ESG in weight loss is significantly greater than that of high-intensity diet and lifestyle therapy and lower than that of laparoscopic sleeve gastrectomy (LSG). The efficacy at 12 months after ESG in terms of percentage of total body weight loss and excess body weight loss was approximately 16% and 60%, respectively. The well-known predictive factors for increased weight loss by ESG are good compliance with regular monitoring and post-procedure care involving a multidisciplinary team approach. Although the underlying mechanism of weight loss induced by ESG is debatable, delayed gastric emptying and early satiation are some of the proposed mechanisms. The pooled rate of adverse events after ESG reported in several meta-analysis studies ranged from 1.5% to 2.3% and the incidence of new-onset gastroesophageal reflux disease after ESG was negligible, indicating that ESG has a superior safety profile to LSG. Moreover, ESG reduced the risk of obesity-related metabolic comorbidities, evidenced by the reduction in HbA1c level, systolic blood pressure, triglyceride level, and risk of hepatic steatosis and fibrosis; it even improved the quality of life. ESG could be considered safe and qualify as an alternative treatment to LSG.

show abstract

“…In contrast, %EWL after ESG remained above 50% at 18-24 months after the procedure. 19 Nonetheless, ESG appears to have less effect in weight reduction than laparoscopic sleeve gastrectomy (LSG). A non-matched cohort study demonstrated that %TWL after ESG was significantly lower compared to LSG both at 6 months (14.4% vs. 23.5%, p <0.001) and 12 months (17.6% vs. 29.3%, p <0.001) after the procedures.…”

Section: Literature Reviewmentioning

confidence: 99%

The First Endoscopic Sleeve Gastroplasty and Transoral Outlet Reduction in Thailand: Case Report and Literature Review

Pausawasdi

2021

Smj

View full text Add to dashboard Cite

Obesity is becoming a universal healthcare problem. The role of endoscopic bariatric and metabolic therapies is emerging in the management of obesity and its related conditions. The endoscopic treatment can be used as a primary weight loss procedure and a revision procedure after bariatric surgery. While the prevalence of obesity has been rising over the past two decades in Thailand, the treatment options have been limited to diet and exercise, pharmacological treatment, and bariatric surgery until recently. In 2020, an endoscopic full-thickness suturing device was introduced to Thailand, leading to successful endoscopic bariatric therapy using a suturing device in Thai patients. This article intends to report the first successful endoscopic sleeve gastroplasty and transoral outlet reduction in Thailand with a mini-review focusing on these two procedures' outcomes.

show abstract

Intragastric Balloon Versus Endoscopic Sleeve Gastroplasty for the Treatment of Obesity: a Systematic Review and Meta-analysis

Cited by 35 publications

References 49 publications

The Clinical and Metabolic Effects of Intragastric Balloon on Morbid Obesity and Its Related Comorbidities

The Clinical and Metabolic Effects of Intragastric Balloon on Morbid Obesity and Its Related Comorbidities

The Efficacy and Safety of Endoscopic Sleeve Gastroplasty as an Alternative to Laparoscopic Sleeve Gastrectomy

The First Endoscopic Sleeve Gastroplasty and Transoral Outlet Reduction in Thailand: Case Report and Literature Review

Contact Info

Product

Resources

About